revenues down due to non-recurring event in 2007, net loss stable
(all figures are in Canadian dollars unless otherwise noted)
BELLEVILLE, ON, Nov. 9 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for the first quarter of its 2008 fiscal year, ending September 30, 2007.
"We are also focused on the successful completion of a marketing partnership deal for Urocidin - our bladder cancer therapy, while executing our Phase III clinical program, the first trial of which continues to recruit patients at 25 centres in the U.S. and Canada," said Graeme McRae, President & CEO of Bioniche Life Sciences Inc. "We also continue to be focused on obtaining a full Canadian license for our E. coli O157:H7 cattle vaccine, while seeking an opportunity to clarify statistical analysis methodology with our U.S. regulator."
Fiscal 2008 First Quarter Financial Results Highlights
Consolidated revenues for the first quarter totaled $5.9 million, a decrease of 23% from the $7.7 million recorded in the same period in Fiscal 2007. A one-time promotion of a leading animal health product contributed to higher revenues for the first quarter last year, an event that was not repeated this year.
The overall gross profit margin was 58% for the first quarter of Fiscal 2008, as compared to 59% for the same period in Fiscal 2007.
Expenses totaled $4.1 million for the three months ending September 30, 2007, which compares to $3.8 million recorded in the same period last year. This increase of $0.3 million, or 8%, primarily reflects additional staff, increased expenditures on E. coli O157:H7 development and awareness program and some necessary salary increases.
Gross research and development expenses remained stable at $3.6 million
for the 3-month periods ending September 30, 2007 and September 30, 2006
respectively. The majo
|SOURCE Bioniche Life Sciences Inc.|
Copyright©2007 PR Newswire.
All rights reserved